Anika Therapeutics Inc (ANIK)

$25.43

-0.26

(-1.01%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Anika Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 41.46M → 42.97M (in $), with an average increase of 3.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -2.74M → -63.0M (in $), with an average decrease of 499.0% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 39.0% return, outperforming this stock by 46.7%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 38.1% return, outperforming this stock by 74.2%

Performance

  • $25.37
    $25.81
    $25.43
    downward going graph

    0.24%

    Downside

    Day's Volatility :1.7%

    Upside

    1.47%

    downward going graph
  • $16.54
    $28.58
    $25.43
    downward going graph

    34.96%

    Downside

    52 Weeks Volatility :42.13%

    Upside

    11.02%

    downward going graph

Returns

PeriodAnika Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
14.43%
-0.7%
0.0%
6 Months
33.45%
6.6%
0.0%
1 Year
-7.66%
3.7%
-1.5%
3 Years
-35.71%
14.0%
-21.8%

Highlights

Market Capitalization
378.8M
Book Value
$14.48
Earnings Per Share (EPS)
-5.64
PEG Ratio
2.23
Wall Street Target Price
30.33
Profit Margin
-49.6%
Operating Margin TTM
56.8%
Return On Assets TTM
-2.36%
Return On Equity TTM
-33.21%
Revenue TTM
166.7M
Revenue Per Share TTM
11.37
Quarterly Revenue Growth YOY
8.5%
Gross Profit TTM
96.8M
EBITDA
2.5M
Diluted Eps TTM
-5.64
Quarterly Earnings Growth YOY
-0.5
EPS Estimate Current Year
0.0
EPS Estimate Next Year
-0.05
EPS Estimate Current Quarter
-0.26
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Buy
    77%Buy
    22%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Anika Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
6
Hold
2
2
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 19.27%

Current $25.43
Target $30.33

Company Financials

FY18Y/Y Change
Revenue
105.6M
↓ 6.93%
Net Income
18.7M
↓ 41.16%
Net Profit Margin
17.74%
↓ 10.31%
FY19Y/Y Change
Revenue
114.6M
↑ 8.58%
Net Income
27.2M
↑ 45.25%
Net Profit Margin
23.73%
↑ 5.99%
FY20Y/Y Change
Revenue
130.5M
↑ 13.83%
Net Income
-24.0M
↓ 188.19%
Net Profit Margin
-18.38%
↓ 42.11%
FY21Y/Y Change
Revenue
147.8M
↑ 13.29%
Net Income
4.1M
↓ 117.24%
Net Profit Margin
2.8%
↑ 21.18%
FY22Y/Y Change
Revenue
156.2M
↑ 5.71%
Net Income
-14.9M
↓ 459.43%
Net Profit Margin
-9.51%
↓ 12.31%
FY23Y/Y Change
Revenue
166.7M
↑ 6.67%
Net Income
-82.7M
↑ 456.34%
Net Profit Margin
-49.6%
↓ 40.09%
Q3 FY22Q/Q Change
Revenue
40.3M
↑ 1.53%
Net Income
-4.2M
↑ 46.85%
Net Profit Margin
-10.37%
↓ 3.2%
Q4 FY22Q/Q Change
Revenue
39.6M
↓ 1.59%
Net Income
-4.9M
↑ 17.56%
Net Profit Margin
-12.39%
↓ 2.02%
Q1 FY23Q/Q Change
Revenue
37.9M
↓ 4.29%
Net Income
-10.4M
↑ 110.88%
Net Profit Margin
-27.29%
↓ 14.9%
Q2 FY23Q/Q Change
Revenue
44.3M
↑ 16.82%
Net Income
-2.7M
↓ 73.52%
Net Profit Margin
-6.19%
↑ 21.1%
Q3 FY23Q/Q Change
Revenue
41.5M
↓ 6.4%
Net Income
-6.6M
↑ 139.91%
Net Profit Margin
-15.86%
↓ 9.67%
Q4 FY23Q/Q Change
Revenue
43.0M
↑ 3.63%
Net Income
-63.0M
↑ 858.03%
Net Profit Margin
-146.61%
↓ 130.75%
FY18Y/Y Change
Total Assets
279.0M
↓ 1.28%
Total Liabilities
15.4M
↓ 19.58%
FY19Y/Y Change
Total Assets
330.7M
↑ 18.54%
Total Liabilities
42.3M
↑ 175.22%
FY20Y/Y Change
Total Assets
365.6M
↑ 10.55%
Total Liabilities
93.2M
↑ 120.18%
FY21Y/Y Change
Total Assets
347.5M
↓ 4.94%
Total Liabilities
60.5M
↓ 35.14%
FY22Y/Y Change
Total Assets
349.1M
↑ 0.46%
Total Liabilities
63.6M
↑ 5.15%
FY23Y/Y Change
Total Assets
270.6M
↓ 22.48%
Total Liabilities
58.4M
↓ 8.18%
Q3 FY22Q/Q Change
Total Assets
347.7M
↓ 1.8%
Total Liabilities
62.8M
↓ 7.59%
Q4 FY22Q/Q Change
Total Assets
349.1M
↑ 0.4%
Total Liabilities
63.6M
↑ 1.2%
Q1 FY23Q/Q Change
Total Assets
339.1M
↓ 2.88%
Total Liabilities
61.5M
↓ 3.27%
Q2 FY23Q/Q Change
Total Assets
328.9M
↓ 3.01%
Total Liabilities
54.9M
↓ 10.77%
Q3 FY23Q/Q Change
Total Assets
328.2M
↓ 0.22%
Total Liabilities
57.7M
↑ 5.11%
Q4 FY23Q/Q Change
Total Assets
270.6M
↓ 17.53%
Total Liabilities
58.4M
↑ 1.21%
FY18Y/Y Change
Operating Cash Flow
34.9M
↓ 14.44%
Investing Cash Flow
-50.3M
↑ 302.7%
Financing Cash Flow
-28.9M
↓ 9305.1%
FY19Y/Y Change
Operating Cash Flow
37.0M
↑ 5.98%
Investing Cash Flow
39.7M
↓ 178.98%
Financing Cash Flow
-8.1M
↓ 71.83%
FY20Y/Y Change
Operating Cash Flow
13.1M
↓ 64.69%
Investing Cash Flow
-71.3M
↓ 279.55%
Financing Cash Flow
-3.8M
↓ 53.65%
FY21Y/Y Change
Operating Cash Flow
8.4M
↓ 35.73%
Investing Cash Flow
-3.1M
↓ 95.62%
Financing Cash Flow
-6.8M
↑ 79.62%
FY22Y/Y Change
Operating Cash Flow
4.4M
↓ 47.49%
Investing Cash Flow
-7.5M
↑ 140.09%
Financing Cash Flow
-4.9M
↓ 28.43%
Q3 FY22Q/Q Change
Operating Cash Flow
2.7M
↓ 12.27%
Investing Cash Flow
-1.7M
↓ 12.84%
Financing Cash Flow
-4.6M
↑ 9923.91%
Q4 FY22Q/Q Change
Operating Cash Flow
481.0K
↓ 82.24%
Investing Cash Flow
-2.5M
↑ 49.56%
Financing Cash Flow
667.0K
↓ 114.47%
Q1 FY23Q/Q Change
Operating Cash Flow
-3.6M
↓ 852.18%
Investing Cash Flow
-1.4M
↓ 45.08%
Financing Cash Flow
-1.6M
↓ 341.83%
Q2 FY23Q/Q Change
Operating Cash Flow
-8.3M
↑ 129.22%
Investing Cash Flow
-1.5M
↑ 4.9%
Financing Cash Flow
-4.9M
↑ 206.45%

Technicals Summary

Sell

Neutral

Buy

Anika Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Anika Therapeutics Inc
Anika Therapeutics Inc
1.66%
33.45%
-7.66%
-35.71%
-18.81%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
-4.7%
35.81%
38.95%
38.38%
112.57%
Resmed Inc.
Resmed Inc.
-8.97%
22.05%
-22.01%
-15.48%
75.2%
Becton, Dickinson And Company
Becton, Dickinson And Company
-2.32%
-10.48%
-8.43%
-10.33%
1.9%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-4.64%
0.62%
4.23%
19.12%
238.38%
Alcon Ag
Alcon Ag
-6.1%
7.94%
11.1%
7.08%
42.78%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Anika Therapeutics Inc
Anika Therapeutics Inc
NA
NA
2.23
0.0
-0.33
-0.02
NA
14.48
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
75.26
75.26
7.13
6.25
0.15
0.08
NA
37.77
Resmed Inc.
Resmed Inc.
30.61
30.61
1.75
7.41
0.22
0.11
0.01
30.47
Becton, Dickinson And Company
Becton, Dickinson And Company
52.86
52.86
1.34
12.95
0.05
0.03
0.02
87.68
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
48.1
48.1
6.72
7.62
0.21
0.12
0.0
39.2
Alcon Ag
Alcon Ag
40.62
40.62
4.59
3.06
0.05
0.02
0.0
41.81
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Anika Therapeutics Inc
Anika Therapeutics Inc
Buy
$378.8M
-18.81%
NA
-49.6%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$134.2B
112.57%
75.26
25.24%
Resmed Inc.
Resmed Inc.
Buy
$27.2B
75.2%
30.61
19.77%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.8B
1.9%
52.86
6.44%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$27.8B
238.38%
48.1
20.12%
Alcon Ag
Alcon Ag
Buy
$39.5B
42.78%
40.62
10.3%

Institutional Holdings

  • Trigran Investments Inc

    14.40%

  • BlackRock Inc

    9.32%

  • Caligan Partners LP

    7.28%

  • Dimensional Fund Advisors, Inc.

    5.53%

  • Vanguard Group Inc

    5.15%

  • Renaissance Technologies Corp

    3.80%

Corporate Announcements

  • Anika Therapeutics Inc Earnings

    Anika Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an

Organization
Anika Therapeutics Inc
Employees
357
CEO
Dr. Cheryl Renee Blanchard Ph.D.
Industry
Health Technology

Discover More

FAQs